Sustained suppression of hepatitis C virus by interferon and ribavirin in hemophilic patients not responding to interferon monotherapy

Santagostino, Elena; Rumi, Maria Grazia; Rivi, Monica; Colombo, Massimo; Mannucci, Pier Mannuccio

doi:10.1182/blood.v99.3.1089

Cited by 25 publications

(24 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies with combination therapy in naive haemophiliacs confirmed this positive trend [9][10][11]. A recent report [12] on 39 HCV-infected haemophilic patients who failed IFN monotherapy showed 37% had sustained virological response after retreatment with IFN in combination with ribavirin. A recent report [12] on 39 HCV-infected haemophilic patients who failed IFN monotherapy showed 37% had sustained virological response after retreatment with IFN in combination with ribavirin.…”

mentioning

confidence: 82%

Interferon and ribavirin in HIV‐negative haemophiliacs with chronic hepatitis C who were nonresponders to a previous interferon treatment

et al. 2002

View full text Add to dashboard Cite

Between January 1999 and December 2001, 33 HIV-negative haemophiliacs with interferon-nonresponsive chronic hepatitis C were treated with interferon (IFN) alpha2b (5 MU three times weekly) and ribavirin (1-1.2 g daily) for 12 months. Four patients (12.1%) dropped out of the study due to adverse effects. At the end of therapy, normalization of ALT occurred in 14/33 treated patients (42.4%) and HCV-RNA was cleared in 12 (36.4%). Eleven patients (33.3%) became sustained responders. Genotype 1 was the only factor associated with a poor response to therapy (P < 0.001). Our study shows that IFN and ribavirin combination therapy is effective in HIV-negative chronically HCV-infected haemophiliacs who do not respond to a previous IFN treatment.

show abstract

mentioning

confidence: 82%

Interferon and ribavirin in HIV‐negative haemophiliacs with chronic hepatitis C who were nonresponders to a previous interferon treatment

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Dose reductions were necessary in 26% of the patients due to side effects. The authors concluded that combined therapy overcomes therapeutic failure to monotherapy in one-third of the patients [15,16]. Lower efficacy of monotherapy with interferon in haemophiliacs had already been documented in a previous study [17].…”

Section: Discussionmentioning

confidence: 85%

Treatment of chronic hepatitis C virus infection among Brazilian haemophiliacs

Pereira

Mangini

2008

Braz J Infect Dis

View full text Add to dashboard Cite

Chronic hepatitis C virus (HCV) infection is now the most important cause of liver cirrhosis and hepatocellular carcinoma worldwide. HCV infection prevalence is high among haemophiliacs (39%-98%), who got infected when received inadequately or non-virus-inactivated large-pool clotting factors concentrates before 1992. Current treatment reduces the probability of developing advanced stages of liver disease. The objective of this study was to evaluate efficacy and safety of the treatment with interferon alpha (IFN) and ribavirin in haemophiliacs. From July 2000 to November 2002, 18 patients were treated with IFN, three million units thrice weekly combined with daily oral doses of 1,000 or 1,250 mg of ribavirin for a minimum of 48 weeks. Eleven patients (61%) showed end of treatment virological response, while nine [(50%): 95% CI: 27-73%] showed sustained virological response as defined by undetectable HCV-RNA six months after treatment. All those nine had persistently undetectable HCV-RNA two to four years post-treatment. There was no treatment interruption due to adverse events. Therefore, the rate of sustained virological response was 50%, with good tolerance.

show abstract

“…50,51 The combination of α-interferon and ribavirin has doubled the effectiveness of α-interferon alone in HCV infection and should be implemented in viremic hemophilic patients before they develop cirrhosis. 52 The favorable experience with the combination of α-interferon and ribavarin is limited mainly to HIV-uninfected hemophiliacs. 52 Perhaps it should now be studied in patients coinfected with HCV and HIV in whom antiretroviral treatment has stabilized HIV infection.…”

Section: Secondary Diseases In Hemophiliamentioning

confidence: 99%

“…52 The favorable experience with the combination of α-interferon and ribavarin is limited mainly to HIV-uninfected hemophiliacs. 52 Perhaps it should now be studied in patients coinfected with HCV and HIV in whom antiretroviral treatment has stabilized HIV infection.…”

Section: Secondary Diseases In Hemophiliamentioning

confidence: 99%